<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04800263</url>
  </required_header>
  <id_info>
    <org_study_id>SHR-1905-I-101-AUS</org_study_id>
    <nct_id>NCT04800263</nct_id>
  </id_info>
  <brief_title>A Trial of SHR-1905 in Healthy Subjects</brief_title>
  <official_title>A Phase 1, Randomized, Double-Blind, Placebo-Controlled Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of Single Subcutaneous Administered SHR-1905 in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Atridia Pty Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Atridia Pty Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, double-blind, placebo-controlled, single dose escalation phase 1 study.&#xD;
      The objective of this study is to evaluate the safety, tolerability, pharmacokinetics and&#xD;
      immunogenicity of subcutaneous administered SHR-1905 in healthy subjects.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will consist of one dose esclation part with a total of 5 dose levels. The Subjects&#xD;
      will be randomized to receive SHR-1905 as reflected by the guiding principle for the dose&#xD;
      esclation/expansion phase. Each dose group includes a screening period, a baseline period, an&#xD;
      observational period, and a safety follow-up period.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 27, 2021</start_date>
  <completion_date type="Anticipated">October 2022</completion_date>
  <primary_completion_date type="Anticipated">March 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse events</measure>
    <time_frame>Start of Treatment to end of study (approximately 16 weeks)</time_frame>
    <description>Incidence and severity of adverse events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics-AUC0-last</measure>
    <time_frame>Start of Treatment to end of study (approximately 16 weeks)</time_frame>
    <description>Area under the concentration-time curve from time 0 to last time point after SHR-1905 administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics-AUC0-inf</measure>
    <time_frame>Start of Treatment to end of study (approximately 16 weeks)</time_frame>
    <description>Area under the concentration-time curve from time 0 to infinity after SHR-1905 administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics-Tmax</measure>
    <time_frame>Start of Treatment to end of study (approximately 16 weeks)</time_frame>
    <description>Time to Cmax of SHR-1905</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics-Cmax</measure>
    <time_frame>Start of Treatment to end of study (approximately 16 weeks)</time_frame>
    <description>Maximum observed concentration of SHR-1905</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics-CL/F</measure>
    <time_frame>Start of Treatment to end of study (approximately 16 weeks)</time_frame>
    <description>Apparent clearance of SHR-1905</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics-Vz/F</measure>
    <time_frame>Start of Treatment to end of study (approximately 16 weeks)</time_frame>
    <description>Apparent volume of distribution during terminal phase of SHR-1905</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics-t1/2</measure>
    <time_frame>Start of Treatment to end of study (approximately 16 weeks)</time_frame>
    <description>Terminal elimination half-life of SHR-1905</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-Drug antibody</measure>
    <time_frame>Start of Treatment to end of study (approximately 16 weeks)</time_frame>
    <description>The percentage of subjects with positive ADA titers over time for SHR-1905</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>SHR-1905 Dose Level 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SHR-1905 Dose level 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SHR-1905 Dose Level 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SHR-1905 Dose level 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SHR-1905 Dose Level 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SHR-1905 Dose level 3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SHR-1905 Dose Level 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SHR-1905 Dose level 4</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SHR-1905 Dose Level 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SHR-1905 Dose level 5</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SHR-1905</intervention_name>
    <description>SHR-1905 will be injected subcutaneously</description>
    <arm_group_label>SHR-1905 Dose Level 1</arm_group_label>
    <arm_group_label>SHR-1905 Dose Level 2</arm_group_label>
    <arm_group_label>SHR-1905 Dose Level 3</arm_group_label>
    <arm_group_label>SHR-1905 Dose Level 4</arm_group_label>
    <arm_group_label>SHR-1905 Dose Level 5</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo will be injected subcutaneously</description>
    <arm_group_label>SHR-1905 Dose Level 1</arm_group_label>
    <arm_group_label>SHR-1905 Dose Level 2</arm_group_label>
    <arm_group_label>SHR-1905 Dose Level 3</arm_group_label>
    <arm_group_label>SHR-1905 Dose Level 4</arm_group_label>
    <arm_group_label>SHR-1905 Dose Level 5</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Ability to understand the trial procedures and possible adverse events, volunteers to&#xD;
             participate in the trial.&#xD;
&#xD;
          2. Male or female aged between 18 years and 55 years (inclusive) at the date of signed&#xD;
             consent form.&#xD;
&#xD;
          3. Total body weight â‰¥45 kg at screening, and body mass index (BMI) between 18 and 28&#xD;
             kg/m2 (inclusive).&#xD;
&#xD;
          4. For healthy subjects, no clinically significant abnormalities.&#xD;
&#xD;
          5. Men and women of childbearing potential (WOCBP) must agree to take effective&#xD;
             contraceptive methods&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Known medical history of severe disease in cardiovascular, liver, kidney, digestive&#xD;
             tract, mental nerve, hematology, metabolic disorders, etc.&#xD;
&#xD;
          2. Severe injuries or major surgeries within 6 months before screening.&#xD;
&#xD;
          3. Subjects with infecious disease.&#xD;
&#xD;
          4. Hyper/Hypotension at screening and at check in.&#xD;
&#xD;
          5. Clinically significant abnormalities in 12-Lead ECG&#xD;
&#xD;
          6. More than 5 cigarettes daily (or products with equivalent amount of nicotine) for 3&#xD;
             months prior to screening&#xD;
&#xD;
          7. Positive urine drug screen .&#xD;
&#xD;
          8. Subject who cannot perform venous blood sampling.&#xD;
&#xD;
          9. Known history or suspected of being allergic to the study drugs and their excipients.&#xD;
&#xD;
         10. Use of any medicine within 4-weeks or within 5 half-lives&#xD;
&#xD;
         11. History of alcohol abuse within 3 months prior to the IP administration .&#xD;
&#xD;
         12. Participation in clinical trials of other investigational drugs or medical devices&#xD;
             within 3 months prior to screening&#xD;
&#xD;
         13. in the investigator's judgment, may increase the risk to the subject&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Na Li</last_name>
    <phone>18964249499</phone>
    <email>na.li@hengrui.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Nucleus Network</name>
      <address>
        <city>Brisbane</city>
        <state>Queensland</state>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>1800 243 733</phone>
    </contact>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>March 11, 2021</study_first_submitted>
  <study_first_submitted_qc>March 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 16, 2021</study_first_posted>
  <last_update_submitted>August 30, 2021</last_update_submitted>
  <last_update_submitted_qc>August 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

